Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660019 | 1.00 | XDH (0.41) | XDHCNR2RORCBRD4CNR1 | |
| SCHEMBL20870363 | 0.82 | SCN9A (0.42) | XDHCNR2RORCBRD4S1PR4 | |
| SCHEMBL29660079 | 0.82 | SCN9A (0.42) | XDHCNR2RORCBRD4S1PR4 | |
| SCHEMBL387265 | 0.79 | GPR119 (0.47) | — | |
| SCHEMBL22262230 | 0.78 | L3MBTL1 (0.40) | XDHCNR2RORCBRD4CNR1 | |
| SCHEMBL27067252 | 0.77 | PDE4D (0.45) | — | |
| SCHEMBL2490015 | 0.76 | KMT2A (0.45) | S1PR4 | |
| SCHEMBL22262261 | 0.76 | OPRK1 (0.47) | XDHRORCBRD4IRAK4SCN9A | |
| SCHEMBL29964807 | 0.76 | CNR2 (0.42) | CNR2CNR1LRRK2OPRK1 | |
| SCHEMBL10176150 | 0.76 | KDM4E (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-111094267-B | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111094267-A | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019063015-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS RORγ INHIBITOR | 正大天晴药业集团股份有限公司 | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | XDH 2362/4885CNR2 492/4885RORC 1/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | XDH 2362/4885CNR2 492/4885RORC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.